Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sustained Human Factor VIII Expression in Hemophilia A Mice Following Systemic Delivery of a Gutless Adenoviral Vector

1 Jan 2002

Abstract excerpt

Gutless adenoviral vectors are devoid of all viral coding regions and display reduced cytotoxicity, diminished immunogenicity, and an increased coding capacity compared with early generation vectors. Using hemophilia A, a deficiency in clotting factor VIII (FVIII), as a model disease, we generated and evaluated a gutless vector encoding human FVIII. The FVIII gutless vector grew to high titer and was reproducibly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 11786047
DOI: 10.1006/mthe.2001.0510

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sustained Human Factor VIII Expression in Hemophilia A Mice Following Systemic Delivery of a Gutless Adenoviral VectorPMID 11786047Read ↗

Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors.Semantic proximity Read ↗

Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primatesSemantic proximity Read ↗

Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia BSemantic proximity Read ↗

Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia ASemantic proximity Read ↗

Current and emerging gene therapies for haemophilia A and BSemantic proximity Read ↗

Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs.Semantic proximity Read ↗

AAV gene therapy in companion dogs with severe hemophilia: Real-world long-term data on immunogenicity, efficacy, and quality of lifeSemantic proximity Read ↗

Promoterless gene targeting without nucleases ameliorates haemophilia B in mice.Semantic proximity Read ↗

Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia ASemantic proximity Read ↗

The intersection of vector biology, gene therapy, and hemophiliaSemantic proximity Read ↗

Adeno-associated virus-based gene therapy for hemophilia–addressing the gapsSemantic proximity Read ↗

Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector deliverySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.